ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

NAS Committee Urges Greater Rewards For Interdisciplinary Research.

January 21, 2005

Sharon Murphy To Head New Research Center in San Antonio

August 2, 2002

NCAB Cool On CCOP, Ponders Questions On Distribution, Numbers Of Centers

December 11, 1981

ASCO Recognizes 15 for Leadership in Clinical Oncology, Updates Genetic Testing Recommendations

May 23, 2003

Letter: The Lesson From Dana-Farber

July 28, 1995

Greenpeace Report Says Chemicals Causing Breast Cancers

October 22, 1993